Navigation Links
China Nepstar Chain Drugstore to Accept TransCard at Shenzhen Outlets
Date:4/2/2008

TransCard Service to Enhance Customer Convenience and Increase Sales

SHENZHEN, China, April 2, 2008 /Xinhua-PRNewswire-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) (''China Nepstar'' or ''the Company''), the largest drugstore chain in China based on the number of directly operated stores, today announced that it has signed an agreement with Shenzhen Tong TransCard Co. Ltd., under which Nepstar will install TransCard POS equipment (TransCard POS readers) in all Shenzhen outlets to enable customers to make purchases with or recharge their TransCards. The TransCard service will add a unique convenience to a customer's shopping experience at Nepstar stores in Shenzhen, and has the potential to generate more sales for these outlets.

The TransCard, similar to the Oyster card used in London and Octopus card used in Hong Kong, is a rechargeable contactless stored value smart card used to transfer electronic payments in online or offline systems in Shenzhen. At present, it is mainly used by cardholders to pay for public transportation in Shenzhen, a city with 8.5 million residents in Guangdong province, Southern China.

TransCard was launched in Shenzhen in April 2006, with the full support of the Shenzhen municipal government. By the end of 2007, over two million cards were sold, driving 1.8 million transactions per day. Currently, one in every five residents in Shenzhen holds a TransCard. Shenzhen Tong TransCard, the issuer and operator of the TransCard service, estimates that an additional four million cards will be sold in 2008.

Nepstar is the operator of the largest drugstore chain in Shenzhen, with 311 outlets as of December 31, 2007. The Company plans to begin the installation of TransCard POS readers in its outlets in May and expects to equip 100 stores with the TransCard POS readers by the end of June. All of Nepstar's Shenzhen stores are expected to provide TransCard service by the end of September 2008.

Mr. Jiannong Qian, CEO of China Nepstar, said, ''The Shenzhen TransCard program is another example of our dedication to offering customers the best possible service and convenience. Our ability to leverage China Nepstar's broad network of stores and develop partnerships with key public vendors, such as Shenzhen Tong TransCard, to increase traffic flow to our stores is a testament to the brand strength we have built and our constant drive for innovation. We are seeking similar opportunities with municipal transit authorities in other cities in China where we have already established an extensive presence. Our goal is to fully integrate China Nepstar into the daily life of urban residents throughout China.''

About China Nepstar Chain Drugstore Ltd.

China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is China's largest retail drugstore chain. As of December 31, 2007, the Company had 2,002 stores in 62 cities and 11 regional distributional centers in China. It uses directly operated stores, centralized procurement and a network of regional distribution centers to provide customers with high-quality, professional and convenient pharmacy services and a wide variety of other merchandise, including over-the-counter ("OTC") drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products including consumables and seasonal and promotional items. China Nepstar's strategy of competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the robust demographic and economic growth trends in China to achieve a strong brand and leading market position. For further information, please go to http://www.nepstar.cn .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute ''forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as ''will,'' ''expects,'' ''anticipates,'' ''future,'' ''intends,'' ''plans,'' ''believes,'' ''estimates'' and similar statements. Among other things, the quotations from management in this press release contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its registration statement on Form F-1. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

For more information, please contact:

In China:

Lucia Qian

China Nepstar Chain Drugstore Ltd.

Marketing and IR Director

Tel: +86-755-2641-4065

Email: qianrt@nepstar.cn

In the United States:

Dixon Chen

The Global Consulting Group

Investor Relations

Tel: +1-646-284-9403

Email: dchen@hfgcg.com

Ivette Almeida

The Global Consulting Group

Media Relations

Tel: +1-646-284-9455

Email: ialmeida@hfgcg.com


'/>"/>
SOURCE China Nepstar Chain Drugstore Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Bionanometer Industries (CBIU) Describes their Current Production Capacity and Product Lines
2. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
3. China Shenghuo Reports Full Year 2007 Financial Results
4. China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results
5. China Medicine Corporation to Present at Brean Murray Carret & Co. Mainland China Investor Tour
6. China Yingxia International, Inc. Announces Record Fourth Quarter and Year 2007 Results
7. China Yingxia International Announces Soybean Milk Production Lines Acquisition
8. Cells from the Research Institute of the MUHC on the road to China
9. China Medicine Announces Record Fourth Quarter and Fiscal Year 2007 Results
10. China Yingxia International Announces 2007 Fourth Quarter and Full Year Financial Results Conference Call
11. China Medicine Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: